NEW YORK (GenomeWeb News) – Vermillion has tapped Thomas McLain to be president and CEO, replacing interim CEO Bruce Huebner, who will retain his position as a company director.

McLain formerly was CEO and CFO of Claro Scientific, an early-stage diagnostic company, and he held senior management positions at Nabi Biopharmaceuticals and was a member of the board of the Biotechnology Industry Organization.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.